Alpha-1 proteinase inhibitor, human

Generic Medicine Info
Indications and Dosage
Adult: As maintenance in patients w/ severe alpha1-proteinase inhibitor deficiency: 60 mg/kg once wkly via infusion approx 0.08 mL/kg/min. Adjust infusion rate based upon patient tolerability.
Hypersensitivity. IgA deficient patients w/ antibodies against IgA.
Special Precautions
Patient at risk for fluid overload. Pregnancy and lactation.
Adverse Reactions
Significant: Risk of infection transmission (e.g. viruses such as Creutzfeldt-Jakob disease). Hypersensitivity reactions (e.g. anaphylaxis).
Nervous: Dizziness, somnolence, flu-like symptoms, headache, paraesthesia, asthenia.
CV: Flushing, chest pain or discomfort hypotension, tachycardia, vasodilatation, peripheral oedema.
GI: Nausea, oral candidiasis, sore throat.
Resp: Dyspnoea, upper resp tract infection, cough, sinusitis.
Hepatic: Increased hepatic enzyme.
Genitourinary: UTI.
Haematologic: Haemorrhage.
Musculoskeletal: Musculoskeletal pain, back pain, weakness.
Dermatologic: Pruritus, urticaria.
Others: Infusion-site reactions, fever, chills.
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
Monitoring Parameters
Closely monitor clinical state (e.g. vital signs), infusion rate, and signs of infusion-related reactions e.g. anaphylactic reactions. Monitor α1-PI serum levels and lung function.
Description: Human alpha-1 proteinase inhibitor is the primary anti-protease in the lower resp tract inhibiting serine proteases e.g. neutrophil elastase, an enzyme that aids in the proteolytic destruction of the connective tissue framework of the lung parenchyma. It protects lung tissue proteolysis in individuals deficient in alpha1-proteinase inhibitor.
Absorption: Time to peak plasma concentration: Approx 1 hr.
Distribution: Volume of distribution: Approx 3.5 L.
Excretion: Elimination half-life: 5-6 days (metabolic).
Store below 25°C.
MIMS Class
Other Drugs Acting on the Respiratory System
Anon. Alpha1-proteinase Inhibitor. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/08/2017.

Anon. Glassia Injection Solution (Baxalta US Inc.). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/08/2017.

Buckingham R (ed). Alpha1-proteinase Inhibitor. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/08/2017.

McEvoy GK, Snow EK, Miller J et al (eds). α1-Proteinase Inhibitor (Human). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 07/08/2017.

Disclaimer: This information is independently developed by MIMS based on Alpha-1 proteinase inhibitor, human from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in